The genetics field is growing quickly, with new companies tackling a wide range of challenges. Their work spans from creating new diagnostic tools to developing treatments for inherited diseases.
Some companies have attracted major funding, like HAYA Therapeutics with $1.1 billion for its RNA-based medicines. Others, such as Colossal Biosciences, are focused on ambitious goals like de-extinction with its $568.1 million in capital.
Below is our list of 55 Genetics startups worth keeping an eye on.
Failory's Top 10 Picks
Tool
Fundraising OS
Everything you need to raise funding for your startup, including 3,500+ investors, 7 tools, 18 templates and 3 learning resources.
Buy It For $97 $297 →Sheet
2,189 Accelerators & Incubators
Information about the industries, countries, and cities they generally invest in.
Get the Sheet for $50Sheet
1,600+ Unicorns
Information about their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
Get the Sheet for $50Sheet
250 BioTech & Health Investors
List of startup investors in the BioTech, Health, and Medicine industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Sheet
250 AI Investors
List of 250 startup investors in the AI and Machine Learning industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Sheet
250 Fintech Investors
List of 250 startup investors in the FinTech and Finance industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Colossal Biosciences applies advanced genetic engineering and synthetic biology to the challenge of de-extinction. They are widely recognized for high-profile projects to resurrect iconic species, most notably the woolly mammoth.
| Headquarters | Austin, Texas, United States |
| Year Founded | 2021 |
| Founders | Andrew Busey, Ben Lamm, Brian Beard, George Church, Kent Wakeford, Peter Phillips |
| Funding Amount | $568.1M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Series C |
| Top Investors | Peter Jackson, Draper Associates, Liquid 2 Ventures, Capital Factory, At One Ventures |
Element Biosciences builds advanced tools for genetic analysis, aiming to make powerful DNA sequencing more accessible. The company's AVITI System provides a versatile benchtop sequencing platform for the research and diagnostics communities.
| Headquarters | San Diego, California, United States |
| Year Founded | 2017 |
| Founders | Matt Kellinger, Michael Previte, Molly He |
| Funding Amount | $678M |
| Startup Size | Large Team (251-1,000) |
| Last Funding Status | Series D |
| Top Investors | Wellington Management, RA Capital Management, Samsung Electronics, Venrock, Fidelity |
Deepcell develops AI-powered technology for life science research, enabling high-resolution single-cell classification and isolation. Their platform provides rich visual data and cell sorting capabilities that support advancements in basic and translational research.
| Headquarters | Menlo Park, California, United States |
| Year Founded | 2017 |
| Founders | Euan Ashley, Maddison Mahdokht Masaeli, Mahyar Salek |
| Funding Amount | $98M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Venture Round |
| Top Investors | Andreessen Horowitz, Fifty Years, Casdin Capital, Stanford University, DCVC |
BillionToOne develops advanced molecular diagnostic tests to make prenatal care and oncology more precise and accessible. Their unique technology enhances the resolution of cell-free DNA, improving disease detection from a single blood sample.
| Headquarters | Menlo Park, California, United States |
| Year Founded | 2016 |
| Founders | David Tsao, Oguzhan Atay, Sukrit Silas |
| Funding Amount | $425.9M |
| Startup Size | Large Team (251-1,000) |
| Last Funding Status | Series D |
| Top Investors | Norwest Venture Partners, 500 Global, HOF Capital, Adams Street Partners, Y Combinator |
Helix created a population genomics platform to help health systems and life sciences organizations use genetic data in clinical care. The platform powers this work through its proprietary Exome+® assay, which creates a reusable genetic dataset for both research and patient health.
| Headquarters | San Mateo, California, United States |
| Year Founded | 2015 |
| Founders | James Lu, Justin Kao, Scott Burke |
| Funding Amount | $403M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Series C |
| Top Investors | Temasek Holdings, Kleiner Perkins, DFJ Growth, Warburg Pincus, National Institutes of Health |
EGenesis uses gene editing and advanced reproductive technologies to develop human-compatible organs for transplantation. Their work in xenotransplantation is designed to address the worldwide organ shortage for patients with end-stage organ failure.
| Headquarters | Cambridge, Massachusetts, United States |
| Year Founded | 2014 |
| Founders | Geoff MacKay, George Church, Luhan Yang |
| Funding Amount | $456M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Series D |
| Top Investors | Khosla Ventures, Lux Capital, ARCH Venture Partners, Catalio Capital Management, Alta Partners |
Ensoma creates one-time genomic medicines that are delivered directly inside the body to treat serious diseases. Their Engenious platform is built for in vivo applications in immuno-oncology and other therapeutic areas.
| Headquarters | Boston, Massachusetts, United States |
| Year Founded | 2019 |
| Founders | Andre Lieber, Hans Peter Kiem |
| Funding Amount | $258M |
| Startup Size | Lean Team (11-50) |
| Last Funding Status | Venture Round |
| Top Investors | Bill & Melinda Gates Foundation, Cormorant Asset Management, Catalio Capital Management, RTW Investments, Gilead Sciences |
Opus Genetics develops gene therapies to address rare inherited retinal diseases. They are focused on creating treatments that can halt disease progression and restore vision for patients with specific genetic mutations.
| Headquarters | Raleigh, North Carolina, United States |
| Year Founded | 2004 |
| Founders | Jason D. Menzo, Jean Bennett, Peter Ginsberg, Rusty Kelley |
| Funding Amount | $22.7M |
| Startup Size | Lean Team (11-50) |
| Last Funding Status | Grant |
| Top Investors | Foundation Fighting Blindness, Bios Partners, Retinal Degeneration Fund, Manning Family Foundation |
HAYA Therapeutics develops precision RNA-guided medicines that target the dark genome. Their work focuses on creating therapies for diseases by acting on previously inaccessible genetic targets.
| Headquarters | Lausanne, Vaud, Switzerland |
| Year Founded | 2017 |
| Founders | Daniel Blessing, Samir Ounzain |
| Funding Amount | $1.1B |
| Startup Size | Lean Team (11-50) |
| Last Funding Status | Grant |
| Top Investors | Eli Lilly, Schroders Capital, MassChallenge, +ND Capital, Apollo Health Ventures |
Kromatid develops molecular cytogenetics assays and reagents to advance the knowledge of genetic abnormalities and diseases. Their products provide tools for researchers to discover and analyze complex structural variations within the genome.
| Headquarters | Longmont, Colorado, United States |
| Year Founded | 2007 |
| Founders | Andrew Ray, Joel Bedford, Michael Cornforth, Susan M. Bailey |
| Funding Amount | $28.1M |
| Startup Size | Lean Team (11-50) |
| Last Funding Status | Series C |
| Top Investors | Small Business Innovation Research, BroadOak Capital Partners, First Capital Ventures |
45 Additional Genetics Startups Worth Following
The top 10 are just a small slice of what’s happening in the genetics field. Together, the companies on our full list have raised over $3.5 billion to push the industry forward.
You'll find companies working in biotech, healthcare, and AI, with some just starting out and others already well established. Here’s a look at the other companies shaping the future of genetics.
